Anthem Biosciences IPO is scheduled to open for subscription on July 14, 2025, and will close on July 16, 2025. The basis of allotment will be finalized on July 17, 2025, followed by refunds and credit to Demat accounts on July 18, 2025. The company is expected to make its stock market debut on July 21, 2025, with listings on both BSE and NSE.
Anthem Biosciences is launching a Book Build Issue IPO to raise approximately ₹3,395 crores, entirely through an offer for sale of 5.96 crore equity shares with a face value of ₹2 each. The price band is fixed at ₹540 to ₹570 per share, and the lot size for retail investors is 26 shares, requiring a minimum investment of ₹14,040. For non-institutional investors, the small NII (sNII) category starts at 14 lots (364 shares) with an investment of ₹2,07,480, and the big NII (bNII) starts at 68 lots (1,768 shares).
The retail quota is 35%, while Qualified Institutional Buyers (QIBs) get 50% and Non-Institutional Investors (HNIs) are allotted 15%. Financially, the company has shown strong growth with a revenue jump from ₹1,483.07 crores in FY 2024 to ₹1,930.29 crores in FY 2025, and a rise in net profit from ₹367.31 crores to ₹451.26 crores in the same period. Given its robust financial performance and market potential, Anthem Biosciences IPO is considered a long-term investment opportunity worth considering.
Overview of Contents
About Anthem Biosciences IPO
Anthem Biosciences Limited, started in 2006, is one of India’s fastest-growing and innovation-driven CRDMO (Contract Research, Development, and Manufacturing Organization) companies. The company offers full services across the entire drug life cycle – from discovery and development to manufacturing – for both small molecules and biologics. They provide advanced research and manufacturing solutions to a wide range of customers, including small biotech startups and large pharmaceutical giants across the globe.
The company is known for making fermentation-based APIs like probiotics, enzymes, peptides, nutritional ingredients, vitamin analogues, and biosimilars. As of September 30, 2024, Anthem Biosciences had over 425 active customers across more than 44 countries, including the USA, Europe, and Japan, and had handled 196 projects – including early and late-phase research and commercial manufacturing.
Their team of around 600 skilled employees includes scientists like medicinal chemists, microbiologists, molecular biologists, and chemical engineers. The company also holds 8 patents (1 in India and 7 abroad) and has filed 24 more patent applications globally. Anthem’s strong focus on innovation, long-term customer relations, and a professional leadership team makes it a trusted partner for pharma and biotech companies worldwide.
Anthem Biosciences IPO Overview
| IPO Details | Information |
|---|---|
| Face Value | ₹2 per equity share |
| Price Band | ₹540 to ₹570 per share |
| Lot Size | 26 Shares |
| Total Issue Size | 5,95,61,404 shares (Approx ₹3,395 Cr) |
| Offer for Sale | Entire issue (No fresh issue) |
| Employee Discount | ₹50 per share |
| Issue Type | Book Building IPO |
| Listing At | BSE & NSE |
| Retail Investor Quota | Not more than 35% |
| QIB Quota | Not more than 50% |
| NII (HNI) Quota | Not more than 15% |
| Pre-Issue Shareholding | 55,90,77,100 shares |
| Post-Issue Shareholding | 55,90,77,100 shares (no change) |
Anthem Biosciences IPO Dates
| Event | Date (Day) |
|---|---|
| IPO Open Date | July 14, 2025 (Monday) |
| IPO Close Date | July 16, 2025 (Wednesday) |
| Basis of Allotment | July 17, 2025 (Thursday) |
| Refunds | July 18, 2025 (Friday) |
| Credit to Demat Account | July 18, 2025 (Friday) |
| IPO Listing Date | July 21, 2025 (Monday) |
Anthem Biosciences IPO Prospectus
| DRHP | Click here |
| RHP | Click here |
Anthem Biosciences IPO Lot Size
The lot size for the Anthem Biosciences IPO is set at 26 shares, and investors can apply in multiples of this lot. The minimum investment for retail investors starts at ₹14,820, while high net-worth individuals (HNIs) can invest significantly higher based on their category. The table below shows the lot-wise investment details:
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 26 | ₹14,820 |
| Retail (Max) | 13 | 338 | ₹1,92,660 |
| S-HNI (Min) | 14 | 364 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1,742 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1,768 | ₹10,07,760 |
Anthem Biosciences IPO Promoter Holding
The promoters of Anthem Biosciences are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, and Ishaan Bhardwaj. Their collective shareholding stands at 77.23% before the IPO, which will slightly reduce to 74.68% post-issue, as the IPO is a complete offer for sale.
Anthem Biosciences IPO Financial Performance
| Financial Metric (₹ in Crore) | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total Assets | 2,807.58 | 2,398.11 | 2,014.46 |
| Revenue | 1,930.29 | 1,483.07 | 1,133.99 |
| Profit After Tax (PAT) | 451.26 | 367.31 | 385.19 |
| EBITDA | 683.78 | 519.96 | 446.05 |
| Net Worth | 2,409.86 | 1,924.66 | 1,740.67 |
| Reserves and Surplus | 2,298.05 | 1,815.39 | 1,628.88 |
| Total Borrowings | 108.95 | 232.53 | 125.06 |
Object of the Issue
- To be Updated
Anthem Biosciences IPO Review
- Sharekhan –
- Canara Bank –
- DRChoksey FinServ –
- Emkay Global –
- Hem Securities –
- IDBI Capital –
- Marwadi Shares –
- Nirmal Bang –
- SBICAP Securities –
- SMC Global –
- Sushil Finance –
- Swastika Investmart –
- Ventura Securities –
- Geojit –
- Reliance Securities –
- Capital Market –
- BP Wealth –
- ICICIdirect –
- Choice Broking –
Anthem Biosciences IPO Registrar
KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: [email protected]
Website: https://kosmic.kfintech.com/ipostatus/
IPO Lead Managers aka Merchant Bankers
- Jm Financial Limited
- Citigroup Global Markets India Private Limited
- J.P. Morgan India Private Limited
- Nomura Financial Advisory And Securities (India) Pvt Ltd
Company Address
Anthem Biosciences Limited
No. 49, F1 & F2, Canara Bank Road
Bommasandra Industrial Area, Phase 1,
Bommasandra,
Bengaluru, Karnataka, 560099
Phone: +91 080 6672 400
Email: [email protected]
Website: https://www.anthembio.com/
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income | Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Syngene International Limited | 12.35 | 51.54 | 11.05% | 117.42 | 3,642.40 Cr. | Syngene International Limited | 12.35 | 51.54 | 11.05% | 117.42 | 3,642.40 Cr. |
| Sai Life Sciences Limited | 8.83 | 92.18 | 10.96% | 102.12 | 1,694.57 Cr. | Sai Life Sciences Limited | 8.83 | 92.18 | 10.96% | 102.12 | 1,694.57 Cr. |
| Suven Life Sciences Limited | 10.52 | 97.29 | 13.61% | 72.31 | 1,197.58 Cr. | Suven Life Sciences Limited | 10.52 | 97.29 | 13.61% | 72.31 | 1,197.58 Cr. |
| Divi’s Laboratories Limited | 82.53 | 83.22 | 15.35% | 564.87 | 9,360.00 Cr. | Divi’s Laboratories Limited | 82.53 | 83.22 | 15.35% | 564.87 | 9,360.00 Cr. |
Anthem Biosciences IPO Valuation – FY2025
| Key Performance Indicator (KPI) | Value |
|---|---|
| Return on Equity (ROE) | 20.82% |
| Return on Capital Employed (ROCE) | 27.64% |
| EBITDA Margin | 36.81% |
| PAT Margin | 23.38% |
| Debt to Equity Ratio | 0.05 |
| Earnings Per Share (EPS - Basic) | ₹8.07 |
| Price/Earnings (P/E) Ratio | N/A |
| Return on Net Worth (RoNW) | 20.82% |
| Net Asset Value (NAV) | ₹43.10 |
Anthem Biosciences IPO FAQs
What is the IPO open and close date for Anthem Biosciences?
The IPO opens on July 14, 2025, and closes on July 16, 2025.
What is the price band of the IPO?
The price band is set at ₹540 to ₹570 per share.
What is the lot size for retail investors?
Retail investors can apply for a minimum of 26 shares per lot, requiring an investment of ₹14,820.
How much is Anthem Biosciences planning to raise through the IPO?
The company aims to raise approximately ₹3,395 crores through a complete Offer for Sale.
Is there any fresh issue in this IPO?
No, the IPO consists entirely of an Offer for Sale with no fresh issue of shares.
When is the Anthem Biosciences IPO allotment date?
The basis of allotment is expected to be finalized on July 17, 2025.
When will shares be credited to the Demat account?
Shares will be credited to investors’ Demat accounts on July 18, 2025.
What is the IPO listing date?
The shares are tentatively scheduled to list on July 21, 2025, on both BSE and NSE.
Who are the promoters of Anthem Biosciences?
The promoters of the company are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, and Ishaan Bhardwaj.
What is the face value of each share?
The face value of each equity share is ₹2.